<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276170</url>
  </required_header>
  <id_info>
    <org_study_id>29957</org_study_id>
    <nct_id>NCT02276170</nct_id>
  </id_info>
  <brief_title>Pharmacology of Aminophylline for Acute Kidney Injury in Neonates</brief_title>
  <acronym>PAANS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) in critically ill neonates is common and associated with
      significant morbidity and mortality. No targeted therapeutic treatment strategies have been
      established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic
      conceptual framework, this project will examine the medication aminophylline as a potential
      treatment approach for AKI.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug concentrations of theophylline</measure>
    <time_frame>Day 1 or 2 and Day 3,4, or 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in renal Near-infrared spectroscopy (NIRS)</measure>
    <time_frame>Day 1,2,3,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine output</measure>
    <time_frame>Day 1,2,3,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine biomarker levels</measure>
    <time_frame>Day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine level</measure>
    <time_frame>Day 1,2,3,4,5</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Aminophylline per standard of care</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Neonates with AKI admitted in the NICU who receive aminophylline.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonate &lt; 3 months post natal age

          -  Diagnosed with acute kidney injury (AKI)

          -  Receiving aminophylline for AKI treatment as per local standard of care.

        Exclusion Criteria:

          -  Presence of anatomical renal anomaly based on postnatal evaluation of the patient
             (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic
             kidney, or obstructive uropathy)

          -  Patient on renal replacement therapy

          -  Major genetic abnormalities (trisomy 13, 18 or 21).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Frymoyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305-5208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stapleton FB, Jones DP, Green RS. Acute renal failure in neonates: incidence, etiology and outcome. Pediatr Nephrol. 1987 Jul;1(3):314-20. Review.</citation>
    <PMID>3153295</PMID>
  </reference>
  <reference>
    <citation>Agras PI, Tarcan A, Baskin E, Cengiz N, GÃ¼rakan B, Saatci U. Acute renal failure in the neonatal period. Ren Fail. 2004 May;26(3):305-9.</citation>
    <PMID>15354981</PMID>
  </reference>
  <reference>
    <citation>Koralkar R, Ambalavanan N, Levitan EB, McGwin G, Goldstein S, Askenazi D. Acute kidney injury reduces survival in very low birth weight infants. Pediatr Res. 2011 Apr;69(4):354-8. doi: 10.1203/PDR.0b013e31820b95ca.</citation>
    <PMID>21178824</PMID>
  </reference>
  <reference>
    <citation>Askenazi DJ, Ambalavanan N, Goldstein SL. Acute kidney injury in critically ill newborns: what do we know? What do we need to learn? Pediatr Nephrol. 2009 Feb;24(2):265-74. doi: 10.1007/s00467-008-1060-2. Epub 2008 Dec 10. Review.</citation>
    <PMID>19082634</PMID>
  </reference>
  <reference>
    <citation>Andreoli SP. Acute kidney injury in children. Pediatr Nephrol. 2009 Feb;24(2):253-63. doi: 10.1007/s00467-008-1074-9. Epub 2008 Dec 13. Review.</citation>
    <PMID>19083019</PMID>
  </reference>
  <reference>
    <citation>Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005 Apr 2-8;365(9466):1231-8.</citation>
    <PMID>15811456</PMID>
  </reference>
  <reference>
    <citation>Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol. 2008 May;3(3):665-73. doi: 10.2215/CJN.04010907. Epub 2008 Mar 12.</citation>
    <PMID>18337554</PMID>
  </reference>
  <reference>
    <citation>Askenazi DJ, Griffin R, McGwin G, Carlo W, Ambalavanan N. Acute kidney injury is independently associated with mortality in very low birthweight infants: a matched case-control analysis. Pediatr Nephrol. 2009 May;24(5):991-7. doi: 10.1007/s00467-009-1133-x. Epub 2009 Feb 24.</citation>
    <PMID>19238451</PMID>
  </reference>
  <reference>
    <citation>Mangione F, Calcaterra V, Esposito C, Dal Canton A. Renal blood flow redistribution during acute kidney injury. Am J Kidney Dis. 2010 Oct;56(4):785-7. doi: 10.1053/j.ajkd.2010.03.035. Epub 2010 Jun 26.</citation>
    <PMID>20580475</PMID>
  </reference>
  <reference>
    <citation>Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011 May 10;57(19):1899-907. doi: 10.1016/j.jacc.2010.11.057.</citation>
    <PMID>21545947</PMID>
  </reference>
  <reference>
    <citation>Lee HT, Xu H, Nasr SH, Schnermann J, Emala CW. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol. 2004 Feb;286(2):F298-306. Epub 2003 Nov 4.</citation>
    <PMID>14600029</PMID>
  </reference>
  <reference>
    <citation>Jenik AG, Ceriani Cernadas JM, Gorenstein A, Ramirez JA, Vain N, Armadans M, Ferraris JR. A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. Pediatrics. 2000 Apr;105(4):E45.</citation>
    <PMID>10742366</PMID>
  </reference>
  <reference>
    <citation>Bakr AF. Prophylactic theophylline to prevent renal dysfunction in newborns exposed to perinatal asphyxia--a study in a developing country. Pediatr Nephrol. 2005 Sep;20(9):1249-52. Epub 2005 Jun 10.</citation>
    <PMID>15947981</PMID>
  </reference>
  <reference>
    <citation>Bhat MA, Shah ZA, Makhdoomi MS, Mufti MH. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. J Pediatr. 2006 Aug;149(2):180-4.</citation>
    <PMID>16887430</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Adam R Frymoyer</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

